Dr. John Hemphill, M.D
NPI: 1285672329
Total Payments
$2.3M
2024 Payments
$385,224
Companies
87
Transactions
4,313
Medicare Patients
6,234
Medicare Billing
$2.8M
Payment Breakdown by Category
Other$1.7M (72.0%)
Travel$297,462 (12.8%)
Consulting$218,223 (9.4%)
Food & Beverage$82,221 (3.5%)
Research$55,113 (2.4%)
Education$1,074 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 626 | 64.7% |
| Travel and Lodging | $297,462 | 548 | 12.8% |
| Consulting Fee | $218,223 | 95 | 9.4% |
| Honoraria | $91,337 | 30 | 3.9% |
| Food and Beverage | $82,221 | 2,927 | 3.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $76,928 | 42 | 3.3% |
| Unspecified | $55,113 | 16 | 2.4% |
| Education | $1,074 | 29 | 0.0% |
Payments by Type
General
$2.3M
4,297 transactions
Research
$55,113
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $283,809 | 281 | $0 (2024) |
| EMD Serono, Inc. | $266,659 | 508 | $0 (2024) |
| Eisai Inc. | $216,279 | 245 | $0 (2024) |
| Amgen Inc. | $190,560 | 245 | $0 (2024) |
| Biogen, Inc. | $183,242 | 265 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $130,823 | 127 | $0 (2024) |
| Allergan, Inc. | $124,109 | 209 | $0 (2022) |
| Horizon Therapeutics plc | $120,377 | 131 | $0 (2023) |
| ABBVIE INC. | $103,274 | 232 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $92,127 | 364 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $385,224 | 539 | Eisai Inc. ($85,733) |
| 2023 | $274,490 | 451 | EMD Serono, Inc. ($67,143) |
| 2022 | $295,631 | 502 | Horizon Therapeutics plc ($45,912) |
| 2021 | $223,180 | 414 | Allergan, Inc. ($30,661) |
| 2020 | $147,868 | 403 | Allergan, Inc. ($35,369) |
| 2019 | $335,007 | 716 | GENZYME CORPORATION ($63,723) |
| 2018 | $359,070 | 681 | GENZYME CORPORATION ($80,647) |
| 2017 | $311,949 | 607 | GENZYME CORPORATION ($123,012) |
All Payment Transactions
4,313 individual payment records from CMS Open Payments — Page 1 of 173
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,890.00 | General |
| Category: Neuroscience | ||||||
| 12/20/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,653.00 | General |
| Category: Neurology | ||||||
| 12/19/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,625.00 | General |
| Category: Neurology | ||||||
| 12/19/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| Category: Neurology | ||||||
| 12/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: Neurology | ||||||
| 12/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,107.50 | General |
| Category: Immunology | ||||||
| 12/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $33.85 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/16/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,107.50 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,755.00 | General |
| Category: Neurology | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $1,564.50 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,462.50 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $35.23 | General |
| Category: Neurology | ||||||
| 12/09/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.86 | General |
| 12/09/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $9.89 | General |
| Category: PAIN | ||||||
| 12/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,237.50 | General |
| Category: Immunology | ||||||
| 12/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,130.00 | General |
| Category: Immunology | ||||||
| 12/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $121.19 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: Neurology | ||||||
| 12/04/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $31.20 | General |
| Category: NEUROSCIENCE | ||||||
| 12/04/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: EPILEPSY | ||||||
| 12/04/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.48 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $26,806 | 2 |
| A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $17,257 | 2 |
| A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis | SANOFI US SERVICES INC. | $7,396 | 4 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,722 | 1 |
| ACP-103-056 | ACADIA Pharmaceuticals Inc | $1,678 | 5 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $153.00 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $100.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 37 | 1,723 | 68,260 | $3.2M | $847,172 |
| 2022 | 36 | 1,587 | 67,777 | $3.5M | $896,600 |
| 2021 | 31 | 1,439 | 49,633 | $1.5M | $417,926 |
| 2020 | 32 | 1,485 | 39,254 | $2.5M | $662,412 |
Total Patients
6,234
Total Services
224,924
Medicare Billing
$2.8M
Procedure Codes
136
All Medicare Procedures & Services
136 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 11 | 7,200 | $1.2M | $335,892 | 28.7% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2023 | 38 | 12,300 | $643,905 | $158,158 | 24.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 56 | 28,085 | $266,808 | $136,012 | 51.0% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 19 | 14,515 | $174,180 | $58,939 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 340 | 488 | $231,800 | $38,356 | 16.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 266 | 348 | $86,873 | $17,427 | 20.1% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 57 | 143 | $63,063 | $14,149 | 22.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 104 | 104 | $50,128 | $11,946 | 23.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 45 | 248 | $30,504 | $11,199 | 36.7% |
| 70551 | Mri scan of brain without contrast | Office | 2023 | 69 | 71 | $88,750 | $6,096 | 6.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 46 | $24,150 | $5,378 | 22.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 39 | 39 | $23,712 | $5,193 | 21.9% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 41 | 41 | $24,086 | $5,076 | 21.1% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 38 | 38 | $54,112 | $4,258 | 7.9% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Office | 2023 | 24 | 24 | $34,344 | $3,795 | 11.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 46 | 86 | $18,060 | $3,740 | 20.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 44 | 50 | $17,500 | $3,365 | 19.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 12 | 12 | $12,192 | $3,258 | 26.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 22 | 35 | $21,000 | $3,234 | 15.4% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 20 | 58 | $12,238 | $3,105 | 25.4% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 11 | 11 | $18,700 | $2,955 | 15.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 29 | 69 | $6,900 | $2,110 | 30.6% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 42 | 49 | $8,183 | $2,024 | 24.7% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 21 | 21 | $12,159 | $1,823 | 15.0% |
| 72141 | Mri scan of upper spinal canal without contrast | Office | 2023 | 20 | 21 | $25,300 | $1,538 | 6.1% |
About Dr. John Hemphill, M.D
Dr. John Hemphill, M.D is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Savannah, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285672329.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Hemphill, M.D has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $385,224 received in 2024. These payments were reported across 4,313 transactions from 87 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Hemphill has provided services to 6,234 Medicare beneficiaries, totaling 224,924 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 136 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Location Savannah, GA
- Active Since 06/02/2006
- Last Updated 05/24/2012
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1285672329
Products in Payments
- LEMTRADA (Drug) $146,372
- Aimovig (Biological) $139,854
- Mavenclad (Drug) $122,711
- AUBAGIO (Drug) $122,342
- UPLIZNA (Drug) $120,112
- BOTOX (Biological) $118,342
- Leqembi (Drug) $115,162
- Fycompa (Drug) $98,956
- OCREVUS (Biological) $78,824
- UBRELVY (Drug) $74,738
- ZEPOSIA (Drug) $70,732
- TYSABRI (Biological) $59,881
- TECFIDERA (Drug) $59,039
- MAVENCLAD (Drug) $52,924
- ULTOMIRIS (Biological) $50,607
- UPLIZNA (Biological) $48,556
- AUSTEDO (Drug) $40,404
- GILENYA (Drug) $39,435
- VYVGART HYTRULO (Drug) $39,220
- Mavenclad (Biological) $38,371
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Savannah
Katherine Moretz, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $153,570
Neurology with Special Qualifications in Child Neurology $153,570
Dr. Eric Pearlman, M.d., Ph.d, M.D., PH.D
Neurology with Special Qualifications in Child Neurology — Payments: $604.33
Neurology with Special Qualifications in Child Neurology $604.33